Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report - Global Forecast till 2023

Report Information
More information from: https://www.marketresearchfuture.com/reports/6947

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Research Report - Global Forecast till 2023

Description:
Global Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Information By Treatment (Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis (Plasma Exchange), Physiotherapy, Others), Diagnosis (Electrodiagnostic Testing, Nerve Conduction, EMG, Spinal Fluid Analysis, Others), By Route of Administration (Intravenous, Oral, Others), By End User (Hospitals, Specialty Neurological Clinics, Research & Academic Laboratories, Others) and Top Regions Forecast till 2023.

Market Snapshots
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare neurological autoimmune disorder where myelin, an essential part of the nervous system is being attacked by the body's immune system. It is a medical condition where the body's immune system fails to differentiate between own cells and foreign cells and starts attacking its healthy cells. As per the analysis of Market Research Future (MRFR), the global chronic inflammatory demyelinating polyneuropathy market is aiming for a CAGR of 6.2% and is due to reach USD 3907.17 Mn by the end of the forecast period of 2018-2023. The global chronic inflammatory demyelinating polyneuropathy market stood at USD 2723.42 Mn in 2017. There has been a spiraling rise in the prevalence of autoimmune disorders in the recent past which offers scope for the growth of the global chronic inflammatory demyelinating polyneuropathy disease market. Patients suffering from autoimmune disorders are more likely to suffer from the disease. Growing incidences of CIDP has evoked major concern within the medical sector, especially in the developed countries. Various public, as well as private organizations, have undertaken initiatives for R&D activities which has yielded positive outcomes in the CIDP space. Noteworthy results have been achieved through rigorous R&D efforts and clinical trials. Various new drugs have been launched into the market after recent FDA approvals which also boosts the growth of the global chronic inflammatory demyelinating polyneuropathy market. Other factors encouraging the growth of the market include surging awareness about the disease and government endeavors regarding the same. On the downside, the high cost of Intravenous immunoglobulin treatment and the side effects accompanied with its administration such as hypotension, nausea, lower back pain, flushing, chills, wheezing, etc. remain hindrance to the growth of the market. Meanwhile, high unmet need for advanced treatment options for the disease is likely to bring to view new opportunities for market players over the forecast period.

Report Overview
This MRFR report provides a forward-looking perspective on the different factors influencing the growth of the Global Chronic Inflammatory Demyelinating Polyneuropathy Market. Drivers, restraints, opportunities, challenges and other factors are discussed in detail to promote a deeper understanding of the market dynamics. The report covers a detailed profile of key players, their market share, geographical presence, strategies adopted by them and changing competition dynamics. Various treatment methods such as intravenous immunoglobulin, corticosteroids, plasmapheresis, physiotherapy, and others are covered. The diverse end user segments included in the report are hospitals, specialty neurological clinics, research & academic laboratories, and others. The report analyzes the key competencies of key players and provides insights into the strategies adopted by them to gain an edge over the market. Geographical presence of each player, their market share, country-level analysis and revenue forecast for each segment has also been provided in the report.

Research Methodology
MRFR provides thoroughly studied market reports by combining the right mix of primary and secondary research methods, to aid clients to achieve their business goals. MRFR's research modules are designed with a specialized approach to meet industry-specific standards. A skilled team of analyst employs primary research techniques such as questionnaires, interviews, and personal interaction with key level market participants to collect valuable information about the market. Data collected from secondary sources such as white papers, annual reports, company websites, paid databases are combined with primary data to provide high-quality, accurate, and unbiased results.

Players Covered

Bio Products Laboratory Ltd., Momenta Pharmaceuticals, Grifols, Baxter, Kedrion S.p.A, Octapharma, Shire, Mitsubishi Tanabe Pharma Corporation, CSL Behring, Teijin Pharma Limited, Pfizer, Inc. are the key players in the global chronic inflammatory demyelinating polyneuropathy market.

Segmental Analysis

By Treatment & Diagnosis

- Treatment
  - Intravenous Immunoglobulin
- Corticosteroids
- Plasmapheresis (plasma exchange)
- Physiotherapy
- Others
- Diagnosis
- Electrodiagnostic Testing
- Nerve Conduction
- EMG
- Spinal Fluid Analysis
- Others

By Route of Administration

- Intravenous
- Oral
- Others

By End User

- Hospitals
- Specialty Neurological Clinics
- Research & Academic Laboratories
- Others

By Region

- The Americas
- Europe
- Asia Pacific
- The Middle East & Africa
TABLE OF CONTENTS

1 Report Prologue
2 Executive Summary
3 Market Introduction
  3.1 Definition 21
  3.2 Scope of the Study 21
  3.3 Research Objective 21
  3.4 Assumptions & Limitations 21
    3.4.1 Assumptions 21
    3.4.2 Limitations 21
  3.5 Market Structure 22
4 Research Methodology
  4.1 Research Process 24
  4.2 Primary Research 25
  4.3 Secondary Research 26
  4.4 Market Size Estimation 27
  4.5 Forecast Model 27
5 Market Dynamics
  5.1 Introduction 29
  5.2 Drivers 30
    5.2.1 Rising prevalence of autoimmune diseases 30
    5.2.2 Increasing research and development related to plasma-derived medicines 30
    5.2.3 Increasing awareness about Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) 30
  5.3 Restraints 31
    5.3.1 Side-effects associated with the Intravenous Immunoglobulin (IVIG) treatment 31
    5.3.2 High cost of the IVIG treatment 31
  5.4 Opportunity 31
    5.4.1 Advancements in the treatment 31
  5.5 Clinical Trials Data 32
6 Market Factor Analysis
  6.1 Porter’s Five Forces Model 34
    6.1.1 Bargaining Power of Suppliers 34
    6.1.2 Bargaining Power of Buyers 34
    6.1.3 Threat of New Entrants 35
    6.1.4 Threat of Substitutes 35
    6.1.5 Intense Rivalry 35
  6.2 Supply Chain Analysis 36
    6.2.1 R&D and Designing 36
    6.2.2 Manufacturing 36
    6.2.3 Distribution & Sales 36
    6.2.4 Post-Sales Monitoring 36
7 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Treatment & Diagnosis
  7.1 Introduction 38
  7.2 Treatment 41
    7.3 Diagnosis 41
8 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Route of Administration
  8.1 Introduction 43
  8.2 Intravenous 44
    8.3 Oral 44
9 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By End User
  9.1 Introduction 46
  9.2 Hospitals 47
    9.3 Specialty Neurological Clinics 47
  9.4 Research & Academic Laboratories 48
10 Global Chronic Inflammatory Demyelinating Polyneuropathy Market, By Region
  10.1 Introduction 50
  10.2 Americas 52
    10.2.1 North America 55
      10.2.1.1 U.S. 57
      10.2.1.2 Canada 59
    10.2.2 South America 61
    10.3 Europe 64
      10.3.1 Western Europe 67
        10.3.1.1 Germany 70
        10.3.1.2 France 72
      10.3.1.3 U.K 74
      10.3.1.4 Italy 76
      10.3.1.5 Spain 78
10.3.1.6 Rest of Western Europe 80
10.3.2 Eastern Europe 82
10.4 Asia Pacific 84
10.4.1 China 87
10.4.2 Japan 89
10.4.3 India 91
10.4.4 Australia 93
10.4.5 Republic of Korea 95
10.4.6 Rest of Asia Pacific 97
10.5 Middle East and Africa 99
10.5.1 Middle East 102
10.5.2 Africa 104

11 Competitive Landscape
11.1 Company Market Share Analysis 107
11.2 Introduction 107

12 Company Profiles
12.1 Grifols 110
12.1.1 Company Overview 110
12.1.2 Financial Overview 110
12.1.3 Products/Services Offered 111
12.1.4 SWOT Analysis 111
12.1.5 Key Developments 111
12.1.6 Key strategy 111
12.2 Shire 112
12.2.1 Company Overview 112
12.2.2 Financial Overview 112
12.2.3 Products/Services Offered 113
12.2.4 SWOT Analysis 113
12.2.5 Key Developments 113
12.2.6 Key strategy 113
12.3 Baxter 114
12.3.1 Company Overview 114
12.3.2 Company Overview 114
12.3.3 Products/Services Offered 115
12.3.4 SWOT Analysis 115
12.3.5 Key Developments 115
12.3.6 Key strategy 115
12.4 Pfizer, Inc. 116
12.4.1 Company Overview 116
12.4.2 Financial Overview 116
12.4.3 Products/Services Offered 117
12.4.4 SWOT Analysis 117
12.4.5 Key Developments 117
12.4.6 Key Strategy 117
12.5 CSL Behring 118
12.5.1 Company Overview 118
12.5.2 Financial Overview 118
12.5.3 Products/Services Offered 119
12.5.4 SWOT Analysis 119
12.5.5 Key Developments 119
12.5.6 Key Strategy 120
12.6 Kedrion S.p.A 121
12.6.1 Company Overview 121
12.6.2 Financial Overview 121
12.6.3 Products/Services Offered 122
12.6.4 SWOT Analysis 122
12.6.5 Key Development 122
12.6.6 Key Strategy 122
12.7 Octapharma 123
12.7.1 Company Overview 123
12.7.2 Financial Overview 123
12.7.3 Products/Services Offered 123
12.7.4 SWOT Analysis 124
12.7.5 Key Development 124
12.7.6 Key Strategy 124
12.8 Momenta Pharmaceuticals 125
12.8.1 Company Overview 125
12.8.2 Financial Overview 125
12.8.3 Products/Services Offered 126
12.8.4 SWOT Analysis 126
12.8.5 Key Development 126
12.8.6 Key Strategy 126
12.9 Teijin Pharma Limited 127
12.9.1 Company Overview 127
12.9.2 Financial Overview 127
12.9.3 Products/Services Offered 128
12.9.4 SWOT Analysis 128
12.9.5 Key Developments 128
12.9.6 Key strategy 128
12.10 Mitsubishi Tanabe Pharma Corporation 129
12.10.1 Company Overview 129
12.10.2 Financial Overview 129
12.10.3 Products/Services Offered 130
12.10.4 SWOT Analysis 130
12.10.5 Key Developments 130
12.11 Bio Products Laboratory Ltd. 131
12.11.1 Company Overview 131
12.11.2 Financial Overview 131
12.11.3 Products/Services Offered 131
12.11.4 SWOT Analysis 131
12.11.5 Key Developments 131
12.11.6 Key strategy 131
13 Appendix
13.1 Discussion Blue Print 133
14 List of Tables
TABLE 1 MARKET SYNOPSIS 19
TABLE 2 PRIMARY INTERVIEWS 24
TABLE 3 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 39
TABLE 4 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE, 2015-2023 (USD MILLION) 40
TABLE 5 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE, 2015-2023 (USD MILLION) 40
TABLE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION) 40
TABLE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY REGION, 2015-2023 (USD MILLION) 41
TABLE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY REGION, 2015-2023 (USD MILLION) 41
TABLE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION) 44
TABLE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR INTRavenous BY REGION, 2015-2023 (USD MILLION) 44
TABLE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ORAL BY REGION, 2015-2023 (USD MILLION) 44
TABLE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET BY END USER, 2015-2023 (USD MILLION) 47
TABLE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR HOSPITALS, BY REGION, 2015-2023 (USD MILLION) 47
TABLE 14 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR SPECIALTY NEUROLOGICAL CLINICS, BY REGION, 2015-2023 (USD MILLION) 47
TABLE 15 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR RESEARCH & ACADEMIC LABORATORIES, BY REGION, 2015-2023 (USD MILLION) 48
TABLE 16 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2015-2023 (USD MILLION) 51
TABLE 17 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 52
TABLE 18 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 52
TABLE 19 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 53
TABLE 20 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 53
TABLE 21 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 53
TABLE 22 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 54
TABLE 23 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 54
TABLE 24 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY, 2015-2023 (USD MILLION) 55
TABLE 25 NORTH AMERICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 55
<table>
<thead>
<tr>
<th>Table</th>
<th>North America Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type, 2015-2023 (USD Million)</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 26</td>
<td>North America Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type, 2015-2023 (USD Million)</td>
<td>55</td>
</tr>
<tr>
<td>Table 27</td>
<td>North America Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>56</td>
</tr>
<tr>
<td>Table 28</td>
<td>North America Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>56</td>
</tr>
<tr>
<td>Table 29</td>
<td>North America Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>57</td>
</tr>
<tr>
<td>Table 30</td>
<td>U.S. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>57</td>
</tr>
<tr>
<td>Table 31</td>
<td>U.S. Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type, 2015-2023 (USD Million)</td>
<td>58</td>
</tr>
<tr>
<td>Table 32</td>
<td>U.S. Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type, 2015-2023 (USD Million)</td>
<td>58</td>
</tr>
<tr>
<td>Table 33</td>
<td>U.S. Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>58</td>
</tr>
<tr>
<td>Table 34</td>
<td>U.S. Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>59</td>
</tr>
<tr>
<td>Table 35</td>
<td>U.S. Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>59</td>
</tr>
<tr>
<td>Table 36</td>
<td>Canada Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>60</td>
</tr>
<tr>
<td>Table 37</td>
<td>Canada Chronic Inflammatory Demyelinating Polyneuropathy Market, by Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>60</td>
</tr>
<tr>
<td>Table 38</td>
<td>Canada Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>60</td>
</tr>
<tr>
<td>Table 39</td>
<td>Canada Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>61</td>
</tr>
<tr>
<td>Table 40</td>
<td>South America Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>61</td>
</tr>
<tr>
<td>Table 41</td>
<td>South America Chronic Inflammatory Demyelinating Polyneuropathy Market, by Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>61</td>
</tr>
<tr>
<td>Table 42</td>
<td>South America Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>61</td>
</tr>
<tr>
<td>Table 43</td>
<td>South America Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>62</td>
</tr>
<tr>
<td>Table 44</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Region, 2015-2023 (USD Million)</td>
<td>64</td>
</tr>
<tr>
<td>Table 45</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>64</td>
</tr>
<tr>
<td>Table 46</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>64</td>
</tr>
<tr>
<td>Table 47</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>64</td>
</tr>
<tr>
<td>Table 48</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>65</td>
</tr>
<tr>
<td>Table 49</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type, 2015-2023 (USD Million)</td>
<td>65</td>
</tr>
<tr>
<td>Table 50</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type, 2015-2023 (USD Million)</td>
<td>65</td>
</tr>
<tr>
<td>Table 51</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>65</td>
</tr>
<tr>
<td>Table 52</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>65</td>
</tr>
<tr>
<td>Table 53</td>
<td>Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>65</td>
</tr>
</tbody>
</table>
TABLE 54 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION) 66
TABLE 55 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION) 66
TABLE 56 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY COUNTRY, 2015-2023 (USD MILLION) 67
TABLE 57 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 67
TABLE 58 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE, 2015-2023 (USD MILLION) 68
TABLE 59 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE, 2015-2023 (USD MILLION) 68
TABLE 60 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION) 68
TABLE 61 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION) 69
TABLE 62 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION) 69
TABLE 63 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 70
TABLE 64 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE, 2015-2023 (USD MILLION) 70
TABLE 65 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE, 2015-2023 (USD MILLION) 70
TABLE 66 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION) 71
TABLE 67 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION) 71
TABLE 68 GERMANY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION) 71
TABLE 69 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 72
TABLE 70 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE, 2015-2023 (USD MILLION) 72
TABLE 71 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE, 2015-2023 (USD MILLION) 72
TABLE 72 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION) 73
TABLE 73 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION) 73
TABLE 74 FRANCE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION) 73
TABLE 75 U.K. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 74
TABLE 76 U.K. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR TREATMENT BY TYPE, 2015-2023 (USD MILLION) 74
TABLE 77 U.K. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR DIAGNOSIS BY TYPE, 2015-2023 (USD MILLION) 74
TABLE 78 U.K. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET FOR ELECTRODIAGNOSTIC TESTING BY TYPE, 2015-2023 (USD MILLION) 75
TABLE 79 U.K. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION) 75
TABLE 80 U.K. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION) 75
TABLE 81 ITALY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2015-2023 (USD MILLION) 76
<table>
<thead>
<tr>
<th>Table</th>
<th>Description</th>
<th>Year Range</th>
<th>Currency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Table 82</td>
<td>Italy Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 83</td>
<td>Italy Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 84</td>
<td>Italy Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 85</td>
<td>Italy Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 86</td>
<td>Italy Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 87</td>
<td>Spain Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 88</td>
<td>Spain Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 89</td>
<td>Spain Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 90</td>
<td>Spain Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 91</td>
<td>Spain Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 92</td>
<td>Spain Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 93</td>
<td>Rest of Western Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 94</td>
<td>Rest of Western Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 95</td>
<td>Rest of Western Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 96</td>
<td>Rest of Western Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 97</td>
<td>Rest of Western Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 98</td>
<td>Rest of Western Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 99</td>
<td>Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 100</td>
<td>Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 101</td>
<td>Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 102</td>
<td>Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 103</td>
<td>Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 104</td>
<td>Eastern Europe Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 105</td>
<td>Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, by Country, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 106</td>
<td>Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023</td>
<td>USD Million</td>
<td></td>
</tr>
<tr>
<td>Table 107</td>
<td>Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 108</td>
<td>Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table 109</td>
<td>Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type</td>
<td>2015-2023</td>
<td>USD Million</td>
</tr>
<tr>
<td>Table No.</td>
<td>Description</td>
<td>Coverage</td>
<td>Page</td>
</tr>
<tr>
<td>-----------</td>
<td>------------------------------------------------------------------------------</td>
<td>----------</td>
<td>------</td>
</tr>
<tr>
<td>Table 110</td>
<td>Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>85</td>
<td></td>
</tr>
<tr>
<td>Table 111</td>
<td>Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Table 112</td>
<td>China Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>Table 113</td>
<td>China Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type, 2015-2023 (USD Million)</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>Table 114</td>
<td>China Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type, 2015-2023 (USD Million)</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>Table 115</td>
<td>China Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Table 116</td>
<td>China Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Table 117</td>
<td>China Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>88</td>
<td></td>
</tr>
<tr>
<td>Table 118</td>
<td>Japan Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Table 119</td>
<td>Japan Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type, 2015-2023 (USD Million)</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Table 120</td>
<td>Japan Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type, 2015-2023 (USD Million)</td>
<td>89</td>
<td></td>
</tr>
<tr>
<td>Table 121</td>
<td>Japan Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Table 122</td>
<td>Japan Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Table 123</td>
<td>Japan Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>90</td>
<td></td>
</tr>
<tr>
<td>Table 124</td>
<td>India Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Table 125</td>
<td>India Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type, 2015-2023 (USD Million)</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Table 126</td>
<td>India Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type, 2015-2023 (USD Million)</td>
<td>91</td>
<td></td>
</tr>
<tr>
<td>Table 127</td>
<td>India Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>Table 128</td>
<td>India Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>Table 129</td>
<td>India Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>92</td>
<td></td>
</tr>
<tr>
<td>Table 130</td>
<td>Australia Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>Table 131</td>
<td>Australia Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment by Type, 2015-2023 (USD Million)</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>Table 132</td>
<td>Australia Chronic Inflammatory Demyelinating Polyneuropathy Market for Diagnosis by Type, 2015-2023 (USD Million)</td>
<td>93</td>
<td></td>
</tr>
<tr>
<td>Table 133</td>
<td>Australia Chronic Inflammatory Demyelinating Polyneuropathy Market for Electrodiagnostic Testing by Type, 2015-2023 (USD Million)</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Table 134</td>
<td>Australia Chronic Inflammatory Demyelinating Polyneuropathy Market, by Route of Administration, 2015-2023 (USD Million)</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Table 135</td>
<td>Australia Chronic Inflammatory Demyelinating Polyneuropathy Market, by End Users, 2015-2023 (USD Million)</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Table 136</td>
<td>Republic of Korea Chronic Inflammatory Demyelinating Polyneuropathy Market, by Treatment &amp; Diagnosis, 2015-2023 (USD Million)</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Table 137</td>
<td>Republic of Korea Chronic Inflammatory Demyelinating Polyneuropathy Market for Treatment</td>
<td>95</td>
<td></td>
</tr>
</tbody>
</table>
TABLE 165 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2015-2023 (USD MILLION) 105
TABLE 166 AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USERS, 2015-2023 (USD MILLION) 105

15 List of Figures
FIGURE 1 RESEARCH PROCESS 24
FIGURE 2 TOP-DOWN & BOTTOM-UP APPROACH 27
FIGURE 3 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET 29
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 34
FIGURE 5 SUPPLY CHAIN: GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET 36
FIGURE 6 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY TREATMENT & DIAGNOSIS, 2017 (%) 39
FIGURE 7 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY TREATMENT & DIAGNOSIS, 2017 & 2023 (USD MILLION) 39
FIGURE 8 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY ROUTE OF ADMINISTRATION, 2017 (%) 43
FIGURE 9 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2017 & 2023 (USD MILLION) 43
FIGURE 10 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY END USER, 2017 (%) 46
FIGURE 11 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY END USER, 2017 & 2023 (USD MILLION) 46
FIGURE 12 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET, BY REGION, 2017 & 2023 (USD MILLION) 50
FIGURE 13 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%) 51
FIGURE 14 AMERICAS CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%) 52
FIGURE 15 EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY REGION, 2017 (%) 64
FIGURE 16 WESTERN EUROPE CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2017 (%) 67
FIGURE 17 ASIA PACIFIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2017 (%) 84
FIGURE 18 MIDDLE EAST AND AFRICA CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY MARKET SHARE, BY COUNTRY, 2017 (%) 99
FIGURE 19 GLOBAL CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) MARKET SHARE ANALYSIS 2017 (%) 107